Completed PHASE3 INTERVENTIONAL NCT00004278

Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection

Sponsor: National Center for Research Resources (NCRR)

Interventions ganciclovir

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Dec 31, 1991

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cytomegalovirus Infections and is currently completed. National Center for Research Resources (NCRR) leads this study, which shows 5 recorded versions since 1991 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 1991

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.